{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:51:05Z","timestamp":1764240665352,"version":"3.41.2"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The newly emerged coronavirus (SARS-CoV-2) is virulent, contagious, and has rapidly gained many mutations, which makes it highly infectious and swiftly transmissible around the world. SARS-CoV-2 infects people of all ages and targets all body organs and their cellular compartments, starting from the respiratory system, where it shows many deleterious effects, to other tissues and organs. Systemic infection can lead to severe cases that require intensive intervention. Multiple approaches were elaborated, approved, and successfully used in the intervention of the SARS-CoV-2 infection. These approaches range from the utilization of single and\/or mixed medications to specialized supportive devices. For critically ill COVID-19 patients with acute respiratory distress syndrome, both extracorporeal membrane oxygenation (ECMO) and hemadsorption are utilized in combination or individually to support and release the etiological factors responsible for the \u201ccytokine storm\u201d underlying this condition. The current report discusses hemadsorption devices that can be used as part of supportive treatment for the COVID-19-associated cytokine storm.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1064459","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T04:51:11Z","timestamp":1682052671000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Blood filtering system for COVID-19 management: novel modality of the cytokine storm therapeutics"],"prefix":"10.3389","volume":"14","author":[{"given":"Vivek P.","family":"Chavda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Raval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soham","family":"Sheta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalitkumar K.","family":"Vora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Elrashdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elrashdy M.","family":"Redwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir N.","family":"Uversky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yavuz Nuri","family":"Ertas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.procbio.2023.01.018","article-title":"Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update","volume":"127","author":"Chavda","year":"2023","journal-title":"Process Biochem Barking Lond Engl"},{"key":"B2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s42247-021-00165-x","article-title":"Role of biomaterials in the diagnosis, prevention, treatment, and study of corona virus disease 2019 (COVID-19)","volume":"4","author":"Ertas","year":"2021","journal-title":"Emergent Mater"},{"key":"B3","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3390\/vaccines11020432","article-title":"Adenoviral vector-based vaccine platform for COVID-19: Current status","volume":"11","author":"Chavda","year":"2023","journal-title":"Vaccines"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0064","article-title":"Therapeutics to tackle omicron outbreak","volume":"8","author":"Chavda","year":"2022","journal-title":"Immunotherapy"},{"key":"B5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2217\/nnm-2020-0441","article-title":"Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): diagnosis, treatment, therapy and future perspectives","volume":"16","author":"Rashidzadeh","year":"2021","journal-title":"Nanomed"},{"key":"B6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3390\/vaccines10030367","article-title":"Is booster dose strategy sufficient for omicron variant of SARS-CoV-2","volume":"10","author":"Chavda","year":"2022","journal-title":"Vaccines"},{"key":"B7","doi-asserted-by":"publisher","first-page":"106727","DOI":"10.1016\/j.ijsu.2022.106727","article-title":"Emergence of novel omicron hybrid variants: BA(x), XE, XD, XF more than just alphabets","volume":"104","author":"Thakur","year":"2022","journal-title":"Int J Surg (London England)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s43440-023-00463-7","article-title":"Nasal sprays for treating COVID-19: a scientific note","volume":"27","author":"Chavda","year":"2023","journal-title":"Pharmacol Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2022.05.014","article-title":"Rare monkeypox: Is it really a threat to the elderly","volume":"15","author":"Chavda","year":"2022","journal-title":"Maturitas"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01446","article-title":"The COVID-19 cytokine storm; what we know so far","volume":"11","author":"Ragab","year":"2020","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0168","article-title":"A global picture: therapeutic perspectives for COVID-19","volume":"14","author":"Chavda","year":"2022","journal-title":"Immunotherapy"},{"key":"B12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1159\/000519166","article-title":"Comparison of the clinical effectiveness of AN69-oXiris versus AN69-ST filter in septic patients: A single-centre study","volume":"51","author":"Zang","year":"2022","journal-title":"Blood Purif"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.3390\/molecules28052332","article-title":"Potential anti-SARS-CoV-2 prodrugs activated by phosphorylation and their role in the aged population","volume":"28","author":"Chavda","year":"2023","journal-title":"Mol Basel Switz"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/biologics1030020","article-title":"Nucleic acid vaccines for COVID-19: A paradigm shift in the vaccine development arena","volume":"1","author":"Chavda","year":"2021","journal-title":"Biologics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"110160","DOI":"10.1016\/j.mehy.2020.110160","article-title":"Apparent difference in fatalities between central Europe and East Asia due to SARS-COV-2 and COVID-19: Four hypotheses for possible explanation","volume":"144","author":"Yamamoto","year":"2020","journal-title":"Med Hypotheses"},{"key":"B17","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3390\/ijerph18010322","article-title":"The early stage of COVID-19 outbreak in Greece: A review of the national response and the socioeconomic impact","volume":"18","author":"Kousi","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B18","doi-asserted-by":"publisher","first-page":"110613","DOI":"10.1016\/j.mehy.2021.110613","article-title":"Does COVID 19 generate a milieu for propagation of mucormycosis","volume":"152","author":"Pandiar","year":"2021","journal-title":"Med Hypotheses"},{"key":"B19","doi-asserted-by":"publisher","first-page":"21501319221099476","DOI":"10.1177\/21501319221099476","article-title":"The past, present and future of COVID-19 associated mucormycosis: A rapid review","volume":"13","author":"Sarfraz","year":"2022","journal-title":"J Prim Care Community Health"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01648","article-title":"Cytokine storm in COVID-19\u2013immunopathological mechanisms, clinical considerations, and therapeutic approaches: The REPROGRAM consortium position paper","volume":"11","author":"Bhaskar","year":"2020","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.10.004","article-title":"Mechanisms of SARS-CoV-2 transmission and pathogenesis","volume":"41","author":"Harrison","year":"2020","journal-title":"Trends Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2013.04.036","article-title":"Cytokine synergy: an underappreciated contributor to innate anti-viral immunity","volume":"63","author":"Bartee","year":"2013","journal-title":"Cytokine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"110493","DOI":"10.1016\/j.biopha.2020.110493","article-title":"Natural history of COVID-19 and current knowledge on treatment therapeutic options","volume":"129","author":"dos Santos","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb8925","article-title":"Cytokine release syndrome in severe COVID-19","volume":"368","author":"Moore","year":"2020","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3390\/biom10091312","article-title":"Why COVID-19 transmission is more efficient and aggressive than viral transmission in previous coronavirus epidemics","volume":"10","author":"Elrashdy","year":"2020","journal-title":"Biomolecules"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-011110-130158","article-title":"The acute respiratory distress syndrome: pathogenesis and treatment","volume":"6","author":"Matthay","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2021.03.002","article-title":"COVID-19 and cytokine storm syndrome: are there lessons from macrophage activation syndrome","volume":"232","author":"Ombrello","year":"2021","journal-title":"Transl Res J Lab Clin Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32013-4","article-title":"Lopinavir\u2013ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"396","author":"Horby","year":"2020","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial","volume":"324","author":"Angus","year":"2020","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00311.2013","article-title":"The mercurial nature of neutrophils: still an enigma in ARDS","volume":"306","author":"Williams","year":"2014","journal-title":"Am J Physiol - Lung Cell Mol Physiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2007.02.014","article-title":"Human immunopathogenesis of severe acute respiratory syndrome (SARS)","volume":"133","author":"Cameron","year":"2008","journal-title":"Virus Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0629-x","article-title":"Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology","volume":"39","author":"Channappanavar","year":"2017","journal-title":"Semin Immunopathol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.actbio.2016.07.015","article-title":"PEGylated PAMAM dendrimers: Enhancing efficacy and mitigating toxicity for effective anticancer drug and gene delivery","volume":"43","author":"Luong","year":"2016","journal-title":"Acta Biomat"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/cbin.11516","article-title":"Serological tests for COVID-19: Potential opportunities","volume":"45","author":"Tantuoyir","year":"2021","journal-title":"Cell Biol Int"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.019","article-title":"Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up","volume":"80","author":"Wang","year":"2020","journal-title":"J Infect"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02555.x","article-title":"Immunosenescence: emerging challenges for an ageing population","volume":"120","author":"Aw","year":"2007","journal-title":"Immunology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12979-019-0165-8","article-title":"Age related human T cell subset evolution and senescence","volume":"16","author":"Li","year":"2019","journal-title":"Immun Ageing A"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2009.03.013","article-title":"CD28(-) T cells: their role in the age-associated decline of immune function","volume":"30","author":"Weng","year":"2009","journal-title":"Trends Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09889-4","article-title":"Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19","volume":"39","author":"Panigrahy","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e139834","DOI":"10.1172\/jci.insight.139834","article-title":"Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease","volume":"5","author":"Zhao","year":"2020","journal-title":"JCI Insight"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05190-5","article-title":"Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment","volume":"39","author":"Soy","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00677","article-title":"Preventing mortality in COVID-19 patients: Which cytokine to target in a raging storm","volume":"8","author":"Lu","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1001\/jamacardio.2020.0950","article-title":"Association of cardiac injury with mortality in hospitalized patients with COVID-19 in wuhan, China","volume":"5","author":"Shi","year":"2020","journal-title":"JAMA Cardiol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99445","article-title":"Neutrophil accumulation and NET release contribute to thrombosis in HIT","volume":"3","author":"Gollomp","year":"2018","journal-title":"JCI Insight"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2177","article-title":"Clotting disorder in severe acute respiratory syndrome coronavirus 2","volume":"31","author":"Pujhari","year":"2021","journal-title":"Rev Med Virol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6019","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.141","article-title":"SMN1 and SMN2 copy numbers in cell lines derived from patients with spinal muscular atrophy as measured by array digital PCR","volume":"3","author":"Stabley","year":"2015","journal-title":"Mol Genet Genomic Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2020.1783243","article-title":"The cytokine storm of COVID-19: a spotlight on prevention and protection","volume":"24","author":"Pearce","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00395-017-0662-x","article-title":"The RISK pathway and beyond","volume":"113","author":"Rossello","year":"2018","journal-title":"Bas Res Cardiol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.310820","article-title":"Critical issues for the translation of cardioprotection","volume":"120","author":"Heusch","year":"2017","journal-title":"Circ Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0008-6363(01)00434-5","article-title":"The inflammatory response in myocardial infarction","volume":"53","author":"Frangogiannis","year":"2002","journal-title":"Cardiovasc Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-007-9026-1","article-title":"Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection","volume":"12","author":"Hausenloy","year":"2007","journal-title":"Heart Fail Rev"},{"key":"B55","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jacc.2018.09.086","article-title":"Multitarget strategies to reduce myocardial Ischemia\/Reperfusion injury: JACC review topic of the week","volume":"73","author":"Davidson","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrcardio.2016.5","article-title":"Ischaemic conditioning and reperfusion injury","volume":"13","author":"Hausenloy","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26232","article-title":"The cytokine storm and COVID-19","volume":"93","author":"Hu","year":"2021","journal-title":"J Med Virol"},{"volume-title":"Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance","year":"2020","key":"B58"},{"key":"B59","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the `Cytokine storm\u2019 in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J Infect"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1706928115","article-title":"MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape","volume":"115","author":"Menachery","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200306-766OC","article-title":"High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome","volume":"168","author":"Ho","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jinf.2006.01.005","article-title":"Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong","volume":"54","author":"Yin-Chun Yam","year":"2007","journal-title":"J Infect"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030343","article-title":"SARS: systematic review of treatment effects","volume":"3","author":"Stockman","year":"2006","journal-title":"PloS Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.586073","article-title":"The artificial-liver blood-purification system can effectively improve hypercytokinemia for COVID-19","volume":"11","author":"Guo","year":"2020","journal-title":"Front Immunol"},{"key":"B66","unstructured":"Pilot study on cytokine filtration in COVID-19 ARDS (CytokCOVID19)\n            Castell\u00e0M"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1039\/c4ob00162a","article-title":"Synthesis of new anionic carbosilane dendrimers via thiol\u2013ene chemistry and their antiviral behaviour","volume":"12","author":"Gal\u00e1n","year":"2014","journal-title":"Org Biomol Chem"},{"key":"B68","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3390\/pathogens12020329","article-title":"The role of immunity in the pathogenesis of SARS-CoV-2 infection and in the protection generated by COVID-19 vaccines in different age groups","volume":"12","author":"Abdulla","year":"2023","journal-title":"Pathogens"},{"key":"B69","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cytogfr.2020.04.002","article-title":"Cytokine storm intervention in the early stages of COVID-19 pneumonia","volume":"53","author":"Sun","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus\u2013induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2020.03.006","article-title":"A promising anti-Cytokine-Storm targeted therapy for COVID-19: The artificial-liver blood-purification system","volume":"7","author":"Zhang","year":"2021","journal-title":"Eng Beijing China."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/art.41285","article-title":"On the alert for cytokine storm: Immunopathology in COVID-19","volume":"72","author":"Henderson","year":"2020","journal-title":"Arthritis Rheumatol Hoboken NJ."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26078","article-title":"COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients","volume":"92","author":"Chakraborty","year":"2020","journal-title":"J Med Virol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13613-021-00905-6","article-title":"Can the cytokine adsorber CytoSorb\u00ae help to mitigate cytokine storm and reduce mortality in critically ill patients? a propensity score matching analysis","volume":"11","author":"Scharf","year":"2021","journal-title":"Ann Intensive Care"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0000000000001761","article-title":"A review of extracorporeal blood purification techniques for the treatment of critically ill coronavirus disease 2019 patients","volume":"68","author":"Niazi","year":"2022","journal-title":"Asaio J"},{"key":"B76","doi-asserted-by":"publisher","first-page":"9852073","DOI":"10.1155\/2016\/9852073","article-title":"Cytokine reduction in the setting of an ARDS-associated inflammatory response with multiple organ failure","volume":"2016","author":"Tr\u00e4ger","year":"2016","journal-title":"Case Rep Crit Care"},{"key":"B77","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000500013","article-title":"What have we learned about the use of cytosorb adsorption columns","volume":"48","author":"Ankawi","year":"2019","journal-title":"Blood Purif"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32008-0","article-title":"Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the extracorporeal life support organization registry","volume":"396","author":"Barbaro","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/aas.14115","article-title":"Mortality and adverse events of hemoadsorption with CytoSorb\u00ae in critically ill patients: A systematic review and meta-analysis of randomized controlled trials","volume":"66","author":"Heymann","year":"2022","journal-title":"Acta Anaesthesiol Scand"},{"key":"B80","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.hrtlng.2020.09.007","article-title":"Cytosorb filter: An adjunct for survival in the COVID-19 patient in cytokine storm? a case report","volume":"50","author":"Rizvi","year":"2021","journal-title":"Heart Lung"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1177\/1751143715574855","article-title":"Early report: The use of CytosorbTM haemabsorption column as an adjunct in managing severe sepsis: initial experiences, review and recommendations","volume":"16","author":"Morris","year":"2015","journal-title":"J Intensive Care Soc"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1159\/000508278","article-title":"Cytokine blood filtration responses in COVID-19","volume":"50","author":"Al Shareef","year":"2021","journal-title":"Blood Purif"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/aor.13864","article-title":"Continuous renal replacement therapy with the addition of CytoSorb cartridge in critically ill patients with COVID-19 plus acute kidney injury: A case-series","volume":"45","author":"Alharthy","year":"2021","journal-title":"Artif Organs"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1111\/jocs.15785","article-title":"Hemoadsorption for management of patients on veno-venous ECMO support for severe COVID-19 acute respiratory distress syndrome","volume":"36","author":"Geraci","year":"2021","journal-title":"J Card Surg"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.773461","article-title":"CytoSorb therapy in COVID-19 (CTC) patients requiring extracorporeal membrane oxygenation: A multicenter, retrospective registry","volume":"8","author":"Song","year":"2021","journal-title":"Front Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jasms.2009.04.023","article-title":"Comparison of CID versus ETD based MS\/MS fragmentation for the analysis of protein ubiquitination","volume":"20","author":"Sobott","year":"2009","journal-title":"J Am Soc Mass Spectrom"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-022-06810-1","article-title":"Hemoperfusion in the intensive care unit","volume":"48","author":"Ricci","year":"2022","journal-title":"Intensive Care Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1159\/000369155","article-title":"Cytokine removal with high cut-off membrane: review of literature","volume":"38","author":"Villa","year":"2014","journal-title":"Blood Purif"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/S1387-3806(01)00583-8","article-title":"Analysis of protein mixtures by matrix-assisted laser desorption ionization-ion mobility-orthogonal-time-of-flight mass spectrometry","volume":"219","author":"Ruotolo","year":"2002","journal-title":"Int J Mass Spectrom"},{"key":"B90","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000508125","article-title":"Extracorporeal blood purification and organ support in the critically ill patient during COVID-19 pandemic: Expert review and recommendation","volume":"50","author":"Ronco","year":"2021","journal-title":"Blood Purif"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.605212","article-title":"PMMA-based continuous hemofiltration modulated complement activation and renal dysfunction in LPS-induced acute kidney injury","volume":"12","author":"Stasi","year":"2021","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s12882-020-02020-3","article-title":"Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)","volume":"21","author":"Asgharpour","year":"2020","journal-title":"BMC Nephrol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13054-021-03597-3","article-title":"Hemofiltration with the seraph\u00ae 100 microbind\u00ae affinity filter decreases SARS-CoV-2 nucleocapsid protein in critically ill COVID-19 patients","volume":"25","author":"Kielstein","year":"2021","journal-title":"Crit Care Lond Engl"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2020.1764369","article-title":"Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients","volume":"42","author":"Chen","year":"2020","journal-title":"Ren Fail"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21883","article-title":"The use of therapeutic plasma exchange as adjunctive therapy in the treatment of coronavirus disease 2019: A critical appraisal of the current evidence","volume":"36","author":"Lu","year":"2021","journal-title":"J Clin Apheresis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1064459\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T04:51:20Z","timestamp":1682052680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1064459\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":95,"alternative-id":["10.3389\/fimmu.2023.1064459"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1064459","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"article-number":"1064459"}}